Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 862

Results For "C"

9098 News Found

LASA receives WHO nod for its Ratnagiri unit
Policy | January 13, 2021

LASA receives WHO nod for its Ratnagiri unit

Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.


States need to capture vaccination data: R. S. Sharma
Policy | January 11, 2021

States need to capture vaccination data: R. S. Sharma

Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.


Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn
News | January 08, 2021

Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn

Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.


Aditya Puri joins as director of Stelis Biopharma
People | January 08, 2021

Aditya Puri joins as director of Stelis Biopharma

Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.


EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
Drug Approval | December 20, 2025

EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease

Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD


GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
Drug Approval | December 20, 2025

GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year

The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials


Gilead’s new HIV therapy shows promising Phase 3 results
Clinical Trials | December 19, 2025

Gilead’s new HIV therapy shows promising Phase 3 results

The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy


Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron
Clinical Trials | December 19, 2025

Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron

At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo


FDA nod to first oral single-dose treatment for gonorrhea
Drug Approval | December 16, 2025

FDA nod to first oral single-dose treatment for gonorrhea

The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership


Godavari Biorefineries ED Sangeeta Srivastava named BRSI Honorary Fellow
People | December 16, 2025

Godavari Biorefineries ED Sangeeta Srivastava named BRSI Honorary Fellow

Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation